Table 1.
Definition of the variables in the model
| Symbol | Definition | Initial value |
|---|---|---|
| [H] | Population of susceptible healthy cells. | 4.0 × 105 cells ml−1 |
| [I] | Population of infected cells. | 0 cells ml−1 |
| [DC] | Population of dendritic cells. | 1.0 × 103 cells ml−1 (Lee et al., 2009) |
| [APCR] | Population of antigen-presenting cells at respiratory tracts. | 0 cells ml−1 |
| [V] | The viral load of free SARS-CoV-2. | 0.31 copies ml−1 (Hernandez-Vargas and Velasco-Hernandez, 2020) |
| [APCL] | Population of antigen-presenting cells at lymph nodes. | 0 cells ml−1 |
| [CD4+T0]] | Population of naive CD4+ T cells. | 1.0 × 103 cells ml−1 (Lee et al., 2009) |
| [Th1] | Population of type I helper T cells. | 0 cells ml−1 |
| [CD8+T0] | Population of naive CD8+ T cells. | 1.0 × 103 cells ml−1 (Lee et al., 2009) |
| [CTLL] | Population of cytotoxic T lymphocyte at lymph nodes. | 0 cells ml−1 |
| [CTLR] | Population of cytotoxic T lymphocyte at respiratory tracts. | 0 cells ml−1 |
| [Tfh] | Population of follicular helper T cells. | 0 cells ml−1 |
| [B0] | Population of naive B cells | 1.0 × 103 cells ml−1 (Lee et al., 2009) |
| [pB] | Population of plasma B cells. | 0 cells ml−1 |
| [Ig] | The fold change in immunoglobulin. This includes antiviral antibodies acting against SARS-CoV-2 that have been acquired upon seasonal human coronavirus infections as well as specific antiviral antibodies that are produced after SARS-CoV-2 infection, because a cohort of SARS-CoV-2–uninfected individuals showed to possess antiviral antibodies against SARS-CoV-2 (Ng et al., 2020). |
110 molecules ml−1 (Lee et al., 2009) |
| [INF1] | The fold change in type-I interferon. | 0 fold change |